0.045 (1.772%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Very Weak
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Very Strong
Earnings
Strong
Growth
Earnings
Very Strong
Dividends
Weak
Quality
Capital Efficiency
Weak
Balance Sheet
Neutral
Website
N/A
Telephone
64.800.423.823
Address
Level 1 129 Hurstmere Road, Takapuna Nielsen House Auckland 0622
Description
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. It operates through the following geographical segments: Australia, New Zealand, Asia, and Rest of the World. The Australia segment caters to the Australian market. The New Zealand segment focuses on the head office function, supplier relationships and procurement of stock, and regulatory, marketing, and finance activities of the group. The Asia segment relates in the sales activities in Brunei, Hong Kong, Malaysia, Philippines, Singapore, and Vietnam markets. The Rest of the World segment consists of out licensing of internet protocol developments to markets in which the firm does not have a presence and the export of products to export markets. The company was founded by Hartley Atkinson and Marree Atkinson on September 4, 1997 and is headquartered in Auckland, New Zealand.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 2.15 - 3.53
Trade Value (12mth)
AU$1,020.00
1 week
-5.93%
1 month
-0.39%
YTD
-1.55%
1 year
-27.84%
All time high
5.25
EPS 3 yr Growth
100.90%
EBITDA Margin
13.20%
Operating Cashflow
$24m
Free Cash Flow Return
22.50%
ROIC
13.80%
Interest Coverage
7.00
Quick Ratio
1.20
Shares on Issue (Fully Dilluted)
105m
HALO Sector
Healthcare
Next Company Report Date
22-May-25
Ex Dividend Date (est.)
19-Jun-24
Next Dividend Pay Date (est.)
04-Jul-24
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
13 January 25 |
NEW YEAR LETTER TO INVESTORS
×
NEW YEAR LETTER TO INVESTORS |
|
02 December 24 |
Disclosure of Directors and Senior Managers Relevant Interes
×
Disclosure of Directors and Senior Managers Relevant Interes |
|
27 November 24 |
Disclosure of Directors and Senior Managers Relevant Interes
×
Disclosure of Directors and Senior Managers Relevant Interes |
|
27 November 24 |
Disclosure of Directors and Senior Managers Relevant Interes
×
Disclosure of Directors and Senior Managers Relevant Interes |
|
21 November 24 |
FY25 Interim Report
×
FY25 Interim Report |
|
21 November 24 |
FY25 Interim Presentation
×
FY25 Interim Presentation |
|
21 November 24 |
FY25 Interim release
×
FY25 Interim release |
|
21 November 24 |
FY25 Interim NZX App2
×
FY25 Interim NZX App2 |
|
13 November 24 |
AFT appoints Allison Yorston as independent director
×
AFT appoints Allison Yorston as independent director |
|
07 November 24 |
Change in substantial holding
×
Change in substantial holding |
|
01 November 24 |
AFT trading update
×
AFT trading update |
|
21 October 24 |
AFT enters late-stage R&D agreement for a novel injectable
×
AFT enters late-stage R&D agreement for a novel injectable |
|
11 October 24 |
Interim results to be announced on Nov 21 2024
×
Interim results to be announced on Nov 21 2024 |
|
30 September 24 |
China and USA updates
×
China and USA updates |
|
08 August 24 |
AFT adds COMBOGESIC Tablets to Hikma Agreement in US
×
AFT adds COMBOGESIC Tablets to Hikma Agreement in US |
|
02 August 24 |
2024 ASM results
×
2024 ASM results |
|
02 August 24 |
2024 ASM presentation
×
2024 ASM presentation |
|
02 August 24 |
2024 ASM Chair address
×
2024 ASM Chair address |
|
09 July 24 |
AFT agrees distribution for Crystaderm in China
×
AFT agrees distribution for Crystaderm in China |
|
01 July 24 |
Retirement of Anita Baldauf
×
Retirement of Anita Baldauf |
|
01 July 24 |
Notice of ASM
×
Notice of ASM |
|
21 June 24 |
Update - Dividend/Distribution - AFP
×
Update - Dividend/Distribution - AFP |
|
04 June 24 |
AFT to launch Maxigesic Rapid in the United States
×
AFT to launch Maxigesic Rapid in the United States |
|
31 May 24 |
Annual Meeting and Closing Date for Director Nominations
×
Annual Meeting and Closing Date for Director Nominations |
|
23 May 24 |
Dividend/Distribution - AFP
×
Dividend/Distribution - AFP |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
